SUTENT (sunitinib) for GIST, Advanced RCC and Advanced pNET

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for SUTENT (sunitinib), indicated for gastrointestinal stream tumors (GISTs), advanced renal cell carcinoma (RCC), and pancreatic neuroendocrine tumors (pNETs)

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 7: Use in Specific Populations
Slide 9: Clinical Pharmacology
Slide 13: Warnings and Precautions
Slide 19: Clinical Safety and Efficacy
Slide 33: Drug Storage and Supply
Slide 36: References

Next hm-slideshow in Slides